Full Press Release Details
Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025.
IRON
Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025
Key Takeaway: Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025
Price reaction · baseline $57.77 (2025-07-18 close) · clean, no other IRON news in the window
day 0 close · peak
+2.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+45%
120-day peak, hindsight
Typical move
3.9%
average across 7 past catalysts
Cash runway
~48 mo
Minimal dilution risk
Lead asset
DISC-0974
Phase 2 · Inflammatory Bowel Disease (IBD)